Abstract
Acute kidney injury is a frequent complication in critically ill patients and often necessitates kidney replacement therapy. Optimising antimicrobial dosing in this population is essential yet challenging owing to altered pharmacokinetics in critical illness and the wide variability of prescriptions utilised in kidney replacement therapy. This case report investigates the pharmacokinetics of cefazolin in a critically ill patient receiving prolonged intermittent kidney replacement therapy, offering insights into dosing considerations in this clinical setting.
Keywords
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
